| 1 |
Feng X, Deng Z, Chen J, Ding Y, Zheng H. A validated UHPLC-MS/MS assay for rapid and sensitive determination of crisaborale in human plasma and its clinico-pharmacokinetic application. Journal of Pharmaceutical and Biomedical Analysis 2023;223:115129. [DOI: 10.1016/j.jpba.2022.115129] [Reference Citation Analysis]
|
| 2 |
Kursewicz C, Fourzali K, Yosipovitch G. Itch and Pain Treatments. Atopic Dermatitis : Inside Out Or Outside in 2023. [DOI: 10.1016/b978-0-323-84744-5.00025-5] [Reference Citation Analysis]
|
| 3 |
Sinha S, Meena N. The Sensitive Skin: Do’s and Don’ts. Skin Diseases in Females 2022. [DOI: 10.1007/978-981-16-6065-8_21] [Reference Citation Analysis]
|
| 4 |
陈 辅. Application Progress of Crisaborole in Dermatology. ACM 2022;12:4891-4896. [DOI: 10.12677/acm.2022.125709] [Reference Citation Analysis]
|
| 5 |
Hon KLE, Chan VPY, Leung AKC. Experimental Drugs with the Potential to Treat Atopic Eczema. J Exp Pharmacol 2021;13:487-98. [PMID: 34012301 DOI: 10.2147/JEP.S259299] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 6 |
Hong JJ, Mosca ML, Hadeler EK, Brownstone ND, Bhutani T, Liao WJ. Genital and Inverse/Intertriginous Psoriasis: An Updated Review of Therapies and Recommendations for Practical Management. Dermatol Ther (Heidelb) 2021;11:833-44. [PMID: 33914293 DOI: 10.1007/s13555-021-00536-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 7 |
Milakovic M, Gooderham MJ. Phosphodiesterase-4 Inhibition in Psoriasis. Psoriasis (Auckl) 2021;11:21-9. [PMID: 33763335 DOI: 10.2147/PTT.S303634] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 8 |
Peña SM, Oak ASW, Smith AM, Mayo TT, Elewski BE. Topical crisaborole is an efficacious steroid-sparing agent for treating mild-to-moderate seborrhoeic dermatitis. J Eur Acad Dermatol Venereol 2020;34:e809-12. [PMID: 32452557 DOI: 10.1111/jdv.16673] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 9 |
Davari DR, Nieman EL, McShane DB, Morrell DS. Current Perspectives on the Management of Infantile Atopic Dermatitis. J Asthma Allergy 2020;13:563-73. [PMID: 33177843 DOI: 10.2147/JAA.S246175] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 10 |
Makins C, Sanghera R, Grewal PS. Off-Label Therapeutic Potential of Crisaborole. J Cutan Med Surg 2020;24:292-6. [PMID: 32133868 DOI: 10.1177/1203475420909794] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 11 |
Fourzali K, Yosipovitch G. Safety considerations when using drugs to treat pruritus. Expert Opin Drug Saf 2020;19:467-77. [PMID: 32064980 DOI: 10.1080/14740338.2020.1728252] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 12 |
Bissonnette R, Pavel AB, Diaz A, Werth JL, Zang C, Vranic I, Purohit VS, Zielinski MA, Vlahos B, Estrada YD, Saint-cyr Proulx E, Ports WC, Guttman-yassky E. Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial. Journal of Allergy and Clinical Immunology 2019;144:1274-89. [DOI: 10.1016/j.jaci.2019.06.047] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 12.3] [Reference Citation Analysis]
|
| 13 |
Ono R, Yagi M, Shoji A, Fujita K, Yoshida M, Ports WC, Purohit VS. Phase 1 study of crisaborole in Japanese healthy volunteers and patients with atopic dermatitis. J Dermatol 2020;47:25-32. [PMID: 31657024 DOI: 10.1111/1346-8138.15123] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 14 |
Robbins AB, Gor A, Bui MR. Topical Crisaborole-A Potential Treatment for Recalcitrant Palmoplantar Psoriasis. JAMA Dermatol 2018;154:1096-7. [PMID: 30090935 DOI: 10.1001/jamadermatol.2018.2397] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 15 |
Demurtas A, Pescina S, Nicoli S, Santi P, Padula C. Development and validation of a simple method for the extraction and quantification of crisaborole in skin layers. Biomed Chromatogr 2019;33:e4664. [PMID: 31342550 DOI: 10.1002/bmc.4664] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 16 |
Nguyen HL, Anderson KR, Tollefson MM. New and Emerging Therapies for Pediatric Atopic Dermatitis. Pediatr Drugs 2019;21:239-60. [DOI: 10.1007/s40272-019-00342-w] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 17 |
Hashim PW, Chima M, Kim HJ, Bares J, Yao CJ, Singer G, Chen T, Genece J, Baum D, Kimmel GW, Nia JK, Gagliotti M, Lebwohl MG. Crisaborole 2% ointment for the treatment of intertriginous, anogenital, and facial psoriasis: A double-blind, randomized, vehicle-controlled trial. J Am Acad Dermatol 2020;82:360-5. [PMID: 31279028 DOI: 10.1016/j.jaad.2019.06.1288] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 18 |
Mcdowell L, Olin B. Crisaborole: A Novel Nonsteroidal Topical Treatment for Atopic Dermatitis. Journal of Pharmacy Technology 2019;35:172-8. [DOI: 10.1177/8755122519844507] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 19 |
Renert-yuval Y, Guttman-yassky E. What’s New in Atopic Dermatitis. Dermatologic Clinics 2019;37:205-13. [DOI: 10.1016/j.det.2018.12.007] [Cited by in Crossref: 36] [Cited by in F6Publishing: 25] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 20 |
Valenzuela Ahumada F, Yumha Laiz J. Actualización en el tratamiento de la dermatitis atópica. Piel 2019;34:180-185. [DOI: 10.1016/j.piel.2018.07.020] [Reference Citation Analysis]
|
| 21 |
Diaz A, Guttman-Yassky E. Topical agents for the treatment of atopic dermatitis. Expert Rev Clin Immunol 2019;15:369-82. [PMID: 30587053 DOI: 10.1080/1744666X.2019.1564038] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 22 |
Mroginski Weber D, Voss GT, de Oliveira RL, da Fonseca CA, Paltian J, Rodrigues K, Rodrigues Ianiski F, Vaucher R, Luchese C, Antunes Wilhelm E. Topic application of meloxicam-loaded polymeric nanocapsules as a technological alternative for treatment of the atopic dermatitis in mice. J Appl Biomed 2018;16:337-43. [DOI: 10.1016/j.jab.2018.03.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 23 |
Li H, Zuo J, Tang W. Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases. Front Pharmacol 2018;9:1048. [PMID: 30386231 DOI: 10.3389/fphar.2018.01048] [Cited by in Crossref: 203] [Cited by in F6Publishing: 212] [Article Influence: 40.6] [Reference Citation Analysis]
|
| 24 |
Farfán-García ED, Castillo-García EL, Soriano-Ursúa MA. More than boric acid: Increasing relevance of boron in medicine. World J Transl Med 2018; 7(1): 1-4 [DOI: 10.5528/wjtm.v7.i1.1] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 25 |
Papier A, Strowd LC. Atopic dermatitis: a review of topical nonsteroid therapy. Drugs Context 2018;7:212521. [PMID: 29632548 DOI: 10.7573/dic.212521] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 26 |
Zebda R, Paller AS. Phosphodiesterase 4 inhibitors. Journal of the American Academy of Dermatology 2018;78:S43-52. [DOI: 10.1016/j.jaad.2017.11.056] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 11.6] [Reference Citation Analysis]
|
| 27 |
Shukla S, Feldman SR, Strowd LC. A safety review of the medications used to treat atopic dermatitis. Expert Opin Drug Saf 2018;17:179-83. [PMID: 29195486 DOI: 10.1080/14740338.2018.1411478] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 28 |
Hoy SM. Crisaborole Ointment 2%: A Review in Mild to Moderate Atopic Dermatitis. Am J Clin Dermatol 2017;18:837-43. [PMID: 29076116 DOI: 10.1007/s40257-017-0327-4] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 29 |
Jackson DG, Cardwell LA, Oussedik E, Feldman SR. Utility of boron in dermatology. J Dermatolog Treat 2020;31:2-12. [PMID: 28789577 DOI: 10.1080/09546634.2017.1363850] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 30 |
Udkoff J, Waldman A, Ahluwalia J, Borok J, Eichenfield LF. Current and emerging topical therapies for atopic dermatitis. Clinics in Dermatology 2017;35:375-82. [DOI: 10.1016/j.clindermatol.2017.03.010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 31 |
Cheape AC, Murrell DF. 2% Crisaborole topical ointment for the treatment of mild-to-moderate atopic dermatitis. Expert Review of Clinical Immunology 2017;13:415-23. [DOI: 10.1080/1744666x.2017.1304820] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 32 |
Ciaravino V, Coronado D, Lanphear C, Chanda S. 2-Year animal carcinogenicity results for crisaborole, a novel phosphodiesterase 4 inhibitor for atopic dermatitis. J Dermatol Sci 2017;87:116-22. [PMID: 28416366 DOI: 10.1016/j.jdermsci.2017.03.020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
|
